FITC-Labeled Recombinant Protein L

INTRODUCTION

QC & Assay Protocol

Citation & Background

Synonym
RPL,Protein L
Source
FITC-Labeled Recombinant Protein L (Cat. No. RPL-PF141) is expressed from human HEK293 cells. It is the FITC labeled form of Recombinant Protein L (Cat. No. RPL-P3141).
Request for sequence
Molecular Characterization
FITC-Labeled Recombinant Protein L is fused with a polyhistidine tag at the N-terminus. The reducing (R) protein migrates as 40-45 kDa in SDS-PAGE.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular seive treatment during purification process.
FITC:Protein Ratio
The FITC to protein molar ratio is 5-7.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
1. 4-8^°C for 12 months in lyophilized state;
2. -70^°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE

Bioactivity-ELISA

Immobilized Yervoy Ipilumimab at 10 μg/mL (100 μL/well) can bind FITC-Labeled Recombinant Protein L (Cat. No. RPL-PF141) with a linear range of 20-156 ng/mL (Ex.488 nm/Em.535 nm) (QC tested).

Request for protocol

Citations
- Linker units and molecular constructs comprising the same
  Authors: TW Chang, et al.
  Journal: US20180264133A1 43363
  Application: FACS
  Request for Full-text
- Construction of an anti‑programmed death‑ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells
  Authors: Jiasen Xie, et al.
  Journal: Oncol Lett 2018
  Application: FACS
  Request for Full-text
- Impact of site-specific conjugation of scFv to multifunctional nanomedicines using second generation maleimide
  Authors: Hervé-Aubert K, et al.
  Journal: Bioconjug Chem 2018
  Application: Immunofluorescence
  Request for Full-text
- Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
  Authors: Alric C, et al.
  Journal: J Nanobiotechnology 2018
  Application: Immunofuorescence
  Request for Full-text
Background
Protein L was isolated from the surface of bacterial species Peptostreptococcus magnus and was found to bind Ig(IgG,IgM,IgA,IgE and IgD) through L chain interaction, from which the name was suggested. Despite this wide-ranging binding capability with respect to Ig classes, Protein L is not a universal immunoglobilin-binding protein. Binding of Protein L to immunoglobulins is restricted to those containing kappa light chains (i.e., k chain of the VL domain). In humans and mice, kappa (k) light chains predominate. The remaining immunoglobulins have lambda (l) light chains. The recombinant protein contains four immunoglobulin (Ig) binding domains (Bdomains) of the native protein. Besides antibody, protein L is also suitable for binding of a wide range of antibody fragments such as Fabs, single-chain variable fragments (scFv), and domain antibodies (Dabs).
References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.